8-K

pi3794.txt

FORM 8-K

================================================================================

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report: October 20, 2005

Date of earliest event reported: October 20, 2005

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware 1-3619 13-5315170

(State or other jurisdiction (Commission File (I.R.S. Employer

of incorporation) (Number) Identification No.)

235 East 42nd Street 10017

New York, New York (Zip Code)

(Address of principal executive offices)

Registrant's telephone number, including area code:

(212) 573-2323

Check the appropriate box below if the Form 8-K filing is intended to

simultaneously satisfy the obligation of the registrant under any of the

following provisions:

[ ] Written communication pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the

Exchange Act (17 CFR 240.14d-2{b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the

Exchange Act (17 CFR 240.13e-4(c))

================================================================================

Item 2.02 Results of Operations and Financial Condition

On October 20, 2005, Pfizer Inc. (the "Company" or "Pfizer") issued a press

release announcing its financial results for the third quarter of 2005. The

information contained in the press release is deemed to be "filed" under the

Securities Exchange Act of 1934 as Exhibit 99.1 to this report, and such press

release is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

Exhibit 99.1 - Press Release of Pfizer Inc. dated October 20, 2005, reporting

Pfizer's financial results for the third quarter of 2005.

Exhibit 99.1 is deemed to be "filed" under the Securities

Exchange Act of 1934 in this Current Report on Form 8-K.

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant

has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Margaret M. Foran

-------------------------------

Margaret M. Foran

Title: Senior Vice President-Corporate

Governance, Associate General

Counsel and Secretary

Dated: October 20, 2005

EXHIBIT INDEX

Exhibit No. Description

----------- --------------------------------------------------------------

99.1 Press Release of Pfizer Inc. dated October 20, 2005, reporting

Pfizer's financial results for the third quarter of 2005.